New data from the PROMISES randomised controlled trial with at-risk patients further affirmed that Prevena Therapy significantly reduced the risk of 90-day surgical site complications (SSCs) and readmissions, when compared with the current standard of care (SOC). In fact, the evidence supporting the efficacy of Prevena Therapy was so strong that the study was terminated before its planned completion¹
4X Reduction in SSCs*
3.4% (5/147) Prevena Therapy vs. 14.3% (21/147) SOC (p=0.0013)**
3X Reduction in readmission rates*
3.4% (5/147) Prevena Therapy vs. 10.2% (15/147) SOC (p=0.0208)**
15% Fewer mean dressing changes*
1.1± 0.3 Prevena Therapy vs. 1.3± 1.0 SOC (p=0.0003)
*Calculation(s) are derived based on relative patient group incidence rate reported in this study.
**Statistically significant (p=<
Note:
Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application.
References
The brands listed above are trademarks of 3M.